Health & Environmental Research Online (HERO)


Print Feedback Export to File
1762238 
Journal Article 
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection 
O'Hagan, DT 
2007 
Yes 
Expert Review of Vaccines
ISSN: 1476-0584 
6 
5 
699-710 
17931151 
WOS:000250656300015 
In preclinical studies, MF59 adjuvant offered improved
protection against influenza virus challenge and significantly reduced the viral load in the
lungs of challenged mice. In humans, MF59 is a safe and potent vaccine adjuvant that has been
licensed in more than 20 countries (Fluad((R)) (Novartis Vaccines and Diagnostics Inc., MA,
USA)). The safety profile of an MF59-adjuvanted vaccine is well established through a large
safety database. MF59 adjuvant has had a significant impact on the immunogenicity of influenza
vaccines in the elderly and in adults who are chronically ill. MF59 has also been shown to have a
significant impact on the immunogenicity of pandemic influenza vaccines. MF59 allows for broader
cross-reactivity against viral strains not included in the vaccine. MF59 has been shown to be
more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad
potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types. 
improved influenza vaccines; MF59 adjuvant; oil-in-water emulsion; vaccine adjuvant